Douglas J. Harrison
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Background Novel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that poses several limitations in RRMS. In this analysis, we aimed to estimate an event‐free survival (EFS) endpoint for RRMS that could be used as a benchmark for future studies. Procedure We performed a retrospective study of patients with RRMS enrolling on 13 single‐agent phase II Children's Oncology Group and legacy group trials from 1997 to 2016. All included trials used radiographic response as their primary activity endpoint. Six‐month EFS was estimated from time of trial enrollment with 95% confidence intervals. Clinical characteristics, including trial of enrollment, sex, age, race, histology, number of prior chemotherapies, and radiographic response were evaluated for their impact on 6‐month EFS. Results We identified 175 patients across 13 trials. The 6‐month EFS was 16.8% (11.6%–22.8%). No differences were seen in 6‐month EFS based on age, sex, race, or histology. There were nonsignificant trends toward improved 6‐month EFS for patients with less than or equal to two prior lines of therapy versus higher than two, for patients enrolled on trials that achieved their primary radiographic response endpoint versus trials that did not, and for patients who achieved complete or partial response compared to those achieving stable disease. Conclusions The prognosis of RRMS enrolled on single‐agent phase II trials is poor. This pooled 6‐month EFS of RRMS on single‐agent trials may be used as a RRMS‐specific benchmark for future single‐agent phase II trials.
Year:
2024
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients with advanced sarcoma. Experimental Design: In this retrospective analysis, investigational treatment characteristics and longitudinal survival outcomes were analyzed in patients with biopsy-confirmed sarcoma enrolled in early-phase trials at MD Anderson Cancer Center from May 2006 to July 2021. Results: Five hundred eighty-seven patients were included [405 soft tissue, 122 bone, 60 gastrointestinal stromal tumor (GIST); median of three prior lines of therapy]. Most common subtypes were leiomyosarcoma (17.2%), liposarcoma (14.0%), and GIST (10.2%). Molecular testing was available for 511 patients (87.1%); 221 patients (37.6%) were treated in matched trials. Overall response rate was 13.1% matched compared with 4.9% in unmatched ( P P P P Conclusions: Enrollment in biomarker-matched early-phase trials is associated with improved outcomes in heavily pretreated patients with metastatic sarcoma. Molecular testing of tumors from patients with advanced sarcoma and enrollment in matched trials is a reasonable therapeutic strategy.
Year:
2024
Collaborators (23)
Janos Roszik
The University of Texas MD Anderson Cancer Center
Christina Lynn Roland
The University of Texas MD Anderson Cancer Center
Neeta Somaiah
Professor and Chair
The University of Texas MD Anderson Cancer Center
Richard Gorlick
The University of Texas MD Anderson Cancer Center
Aung Naing
The University of Texas MD Anderson Cancer Center
Vivek Subbiah
Professor of Medicine and of Pediatrics
Stanford University
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Shreyaskumar Patel
Professor
The University of Texas MD Anderson Cancer Center
Justin Moyers
-
Anthony P. Conley
Associate Professor
The University of Texas MD Anderson Cancer Center
Sarina Piha-Paul
Professor
The University of Texas MD Anderson Cancer Center
Siqing Fu
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
J Andrew Livingston
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
VINOD RAVI
Associate Professor
The University of Texas MD Anderson Cancer Center
Valerae Lewis
Professor and Chair
MD Anderson Cancer Center
Cynthia Herzog
Professor
MD Anderson Cancer Center
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Wei-Lien Wang
Associate Professor
The University of Texas MD Anderson Cancer Center
Timothy Yap
The University of Texas MD Anderson Cancer Center
Ravin Ratan
Assistant Professor
The University of Texas MD Anderson Cancer Center
Shubham Pant
Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.